10-Q · May 15, 2026
IGC Pharma reported a decline in revenue and margins for Q1 2026, with revenue at $317,000, down 4% from $330,000 in Q1 2025. The company continues to face challenges with increasing operating expenses, leading to a…
Earnings analysis · 10-Q
IGC earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
IGC reported $191,000 of quarterly revenue, down 39.7% sequentially and 53.6% year over year, with diluted EPS of negative $0.02. Gross margin improved to 51.8%, but operating margin deteriorated to negative 1,517.8%…
Read full summary
IGC reported $191,000 of quarterly revenue, down 39.7% sequentially and 53.6% year over year, with diluted EPS of negative $0.02. Gross margin improved to 51.8%, but operating margin deteriorated to negative 1,517.8% and free cash flow was negative $2 million. The filing provides no numeric guidance and highlights substantial funding needs, including approximately $937 thousand of convertible instruments and ongoing clinical and regulatory uncertainty around the Phase 2 CALMA trial.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
From revenue to operating profit
Where each $100 of revenue went in this report.
Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.02
What stood out
-
Revenue Declined Sequentially and Year Over Year
Revenue was $191,000, down 39.7% from $317,000 in the prior quarter and down 53.6% from $412,000 in the prior-year quarter.
-
Gross Margin Recovered
Gross margin improved to 51.8% from 17.4% sequentially and 48.1% year over year, a gain of 34.4 and 3.7 percentage points, respectively.
-
CALMA Trial Reached Target Enrollment
The Phase 2 CALMA trial reached target enrollment, although patient follow-up, evaluability, database lock, and topline timing remain uncertain.
-
Debt Settlement Agreement Reached
The company entered agreements for the future issuance of 4,274,853 shares at $0.27 per share to cancel $1,154,210 of outstanding amounts.
-
No Reported Control Deficiencies
Management reported that disclosure controls were effective as of June 30, 2026, and that there were no material changes in internal control over financial reporting during the quarter.
What to watch
-
Severe Operating Losses and Cash Burn
Operating margin deteriorated to negative 1,517.8% from negative 775.4% in the prior quarter and negative 427.2% in the prior-year quarter, while free cash flow worsened to negative $2 million from negative $1 million in both comparison periods.
-
Substantial Additional Funding Required
The company states that it will require substantial additional capital to develop IGC-AD1 and other candidates. During the six months ended June 30, 2026, it issued VFG notes with approximately $591 thousand of aggregate principal and received approximately $470 thousand of net proceeds.
-
Discounted Convertible Debt Dilution
As of June 30, 2026, convertible instruments had approximately $937 thousand of aggregate principal and could convert at 75% of the lowest trading price following an event of default, creating material dilution risk despite a 4.99% beneficial-ownership limitation and 19.99% issuance cap.
-
Clinical and Regulatory Uncertainty
The company identifies material execution and regulatory risks for the Phase 2 CALMA trial, including delays in database lock and topline results, inconclusive safety or efficacy results, and potential FDA requests for additional studies.
-
Emerging AI Development Risk
The company’s MINT-AD platform and other artificial-intelligence tools may produce inaccurate or non-generalizable results and may face evolving FDA oversight, creating additional development risk.
Management's outlook
No quantitative revenue or EPS outlook was provided in the filing; prior analysis also indicated that guidance was not updated.
Earlier filings 4
10-Q · November 14, 2025
IGC Pharma's Q2 FY2025 results reflect a significant downturn in revenue, reporting a decline to $191,000, nearly 54% less than the prior-year quarter's revenue of $412,000. The company continues to incur losses, with…
10-Q · August 14, 2025
IGC Pharma reported a solid increase in revenue and improved EPS compared to the prior year. Revenue was $328,000, a 21% increase from $272,000 in the same quarter last year, while the net loss narrowed to $1.599…
10-K · June 27, 2025
IGC Pharma's 10-K report for the fiscal year ending March 31, 2025, highlights a continued focus on developing its lead investigational drug IGC-AD1 for Alzheimer's disease amidst ongoing financial challenges, including…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.